Zenobia Therapeutics

Executive Summary

Zenobia Therapeutics is a San Diego-based biotechnology company founded in 2019, specializing in the development of novel antibody-drug conjugates (ADCs) for solid tumors. The company integrates proprietary antibody engineering with innovative cytotoxic payload technologies to create targeted cancer therapies with improved efficacy and safety profiles. While still in preclinical stages, Zenobia aims to address key limitations of existing ADCs, such as off-target toxicity and limited therapeutic windows. The company's approach leverages advancements in linker chemistry and payload design to enhance tumor-specific delivery and minimize systemic exposure. Given the competitive ADC landscape, Zenobia's success hinges on its ability to differentiate its candidates through superior selectivity and tolerability. The company has not publicly disclosed financial details or a specific lead program, but its foundational technology platform positions it for potential partnerships or further development as it advances toward clinical entry. With a small team and early-stage focus, Zenobia represents a high-risk, high-reward opportunity in the oncology space, dependent on successful preclinical validation and subsequent clinical proof-of-concept.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead ADC candidate30% success
• Q2 2026Presentation of preclinical data at major oncology conference (e.g., ASCO or AACR)60% success
• Q3 2026Announcement of strategic partnership or licensing deal for ADC platform40% success